This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. This study will specifically target older ACL reconstruction patients with concomitant meniscal injuries as this group is at greatest risk of rapid PTOA progression. Patients will randomly be assigned to receive oral montelukast (10 mg) versus placebo daily for 6 months after surgery.
Age range
25 Years – 50 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Serum prostaglandin E2
Timeframe: Change between Visit 3 (10 days post surgery) and Visit 6 (1 year post surgery)
T1rho relaxation time on MRI
Timeframe: Change between Visit 4 (4 weeks post surgery) and Visit 6 (1 year post surgery)
Shape of the medial femoral condyle on MRI
Timeframe: Change between Visit 4 (4 weeks post surgery) and Visit 6 (1 year post surgery)
Knee injury and Osteoarthritis Outcome Score (KOOS)
Timeframe: Change between Visit 3 (10 days post surgery) and Visit 6 (1 year post surgery)